DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1762)

Immune Thrombocytopenic Purpura | Landscape & Forecast | Disease Landscape & Forecast

Immune Thrombocytopenic Purpura | Landscape & Forecast | Disease Landscape & Forecast

Thank you!

Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.

Immune thrombocytopenic purpura ( ITP ) is a hematological autoimmune disorder characterized by low platelet count in the blood, which may lead to easy bruising and bleeding. ITP has an acute, generally self-limiting form that typically affects children and a chronic form that affects adults. For many years, immune-modulating therapies, such as corticosteroids, immunoglobulins ( IVIG and anti-RhD), and rituximab, were the mainstays of treatment in ITP . However, the approval of thrombopoietin -receptor agonists ( TPO - RA s), eltrombopag ( Promacta ) and romiplostim ( Nplate ), starting in 2008, revolutionized the treatment landscape of ITP by opening new and highly effective avenues of treatment other than immunomodulation . Despite the availability of many effective therapies, a significant proportion of patients exist who are either unresponsive or refractory to available treatments. The late-phase clinical pipeline of ITP comprises a spleen tyrosine kinase ( Syk ) inhibitor, Tavalisse, and a second-generation oral TPO - RA , avatrombopag, both of which are expected to launch in the next few years. The early-phase ITP pipeline includes mostly immunomodulating agents, such as inhibitors of CD20, CD40, Fc receptors, and Syk signaling. Although there are many available treatments and a sizable emerging therapy pipeline, the ITP landscape has ample scope and market opportunity for development of agents based on novel therapeutic approaches, particularly agents that can target the specific underlying causes of disease.
Questions Answered

How will the size of the ITP population change through 2027?
What are key current therapies in the ITP market? What will be their commercial contribution to the ITP market in 2027?
What are the key drug targets emerging from basic and clinical research in ITP ? Which emerging therapies do ITP experts consider most promising? How would new therapies influence management of ITP patients?
How are emerging ITP drugs being evaluated, and which are likely to launch by 2027? What commercial impact will they have on the ITP market?

Product Description
Niche & Rare Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

  • Pub Date: April 2018
  • Author(s): Akash Saini, PhD

Request report

Related reports: